摘要
目的比较以坏死为主的鼻腔恶性淋巴瘤（原诊断为坏死性肉芽肿）和以新生物为主的鼻腔淋巴瘤临床预后的差异。方法１９９１年３月～１９９６年６月我院收治的免疫组化证实的鼻腔恶性淋巴瘤７６例，其中３５例临床表现以坏死、溃疡或伴恶臭为主，免疫组化检测均为Ｔ细胞淋巴瘤。ＡｎｎＡｒｂｏｒ分期Ⅰ，Ⅱ期。采用局部放射治疗和（或）全身化疗。数据用Ｋａｐｌａｎ－Ｍｅｉｅｒ法分析，Ｌｏｇ－ｒａｎｋ检验。结果以坏死为主的鼻腔恶性淋巴瘤和以新生物为主的鼻腔恶性淋巴瘤５年生存率分别为４３％和４９％（Ｐ＝０．５９）。５年无瘤生存率分别为３９％和４２％（Ｐ＝０．８１）。５年局控率分别为８９％和９５％（Ｐ＝０．２８）。５年远处侵犯率分别为２０％和２６％（Ｐ＝０．０９）。结论以坏死为主的鼻腔恶性淋巴瘤和以新生物为主的鼻腔恶性淋巴瘤，两者临床预后差异无显著意义，为同一组疾病两种不同的表型。
Objective To compare the therapeutic results of nasal cavity lymphoma with necrosis or tumor mass as the chief manifestation.Methods Seventy six cases of nasal cavity lymphoma proven by immunohistochemistry received local radiotherapy and/or chemotherapy from Mar. 1991 to Jun. 1996. Thirty five cases who had been characterized by progressive necrosis,unrelenting ulceration of nasal cavity and midline facial tissue with offensive odor,formerly so called nasal lethal midline granuloma were proven to be Tcell lymphoma. Forty one cases were characterized by tumor mass in the nasal cavity (24 Tcell lineage,17 Bcell lineage). The data were analyzed with KaplanMeier method and Logrank test in computer software SPSS 7.5.Results The 5 year survival rates of nasal cavity lymphoma with necrosis and with tumor mass were 43% and 49% (P=0.59), respectively. Their 5 year diseasefreesurvival rates were 39% and 42%(P=0.81); The 5 year local control rates and distant invasion rates were 89%,95%(P= 0.28 ) and 20%,26%(P=0.09).Conclusions Nasal lethal midline granuloma is one kind of nasal cavity lymphoma. Although nasal cavity lymphoma with necrosis and with tumor mass have different clinical manifestations and different immunohistochemical phenotypes, they have the same therapeutic results and prognosis. They should be taken as two kinds of phenotype of the same disease entity.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
1999年第1期9-11,共3页
Chinese Journal of Radiation Oncology
关键词
淋巴瘤
预后
鼻肿瘤
坏死性
新生物
Lymphoma Lethal midline granuloma Prognosis Nose neoplasms
